Gastroenterology
Volume 136, Issue 4 , Pages 1206-1214 , April 2009

Prospective Derivation and Validation of a Clinical Prediction Rule for Recurrent Clostridium difficile Infection

  • Mary Y. Hu

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    • ,
  • Kianoosh Katchar

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    • ,
  • Lorraine Kyne

      Affiliations

    • Department of Medicine for the Older Person, Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland
    • ,
  • Seema Maroo

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    • ,
  • Sanjeev Tummala

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    • ,
  • Valley Dreisbach

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    • ,
  • Hua Xu

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    • ,
  • Daniel A. Leffler

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    • ,
  • Ciarán P. Kelly

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    • Corresponding Author InformationReprint requests Address requests for reprints to: Ciarán P. Kelly, MD, Associate Professor of Medicine, Harvard Medical School, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Dana 601, Boston, Massachusetts 02215. fax: 617-667-8144

Received 9 June 2008 ,Accepted 11 December 2008.

References 

  1. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med. 1994;330:257–262
  2. Kyne L, Farrell RJ, Kelly CP. Clostridium difficile. Gastroenterol Clin North Am. 2001;30:753–777
  3. Bartlett JG, Chang TW, Gurwith M, et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med. 1978;298:531–534
  4. Larson HE, Price AB, Honour P, et al. Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet. 1978;1:1063–1066
  5. Fekety R American College of Gastroenterology, Practice Parameters Committee. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol. 1997;92:739–750
  6. Kyne L, Kelly CP. Recurrent Clostridium difficile diarrhoea. Gut. 2001;49:152–153
  7. Maroo S, Lamont JT. Recurrent Clostridium difficile. Gastroenterology. 2006;130:1311–1316
  8. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis. 2005;5:549–557
  9. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med. 2006;145:758–764
  10. Wilcox MH, Spencer RC. Clostridium difficile infection: responses, relapses and re-infections. J Hosp Infect. 1992;22:85–92
  11. Olson MM, Shanholtzer CJ, Lee JT, et al. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol. 1994;15:371–381
  12. Fekety R, McFarland LV, Surawicz CM, et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis. 1997;24:324–333
  13. McFarland LV, Surawicz CM, Rubin M, et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol. 1999;20:43–50
  14. Tedesco FJ. Treatment of recurrent antibiotic-associated pseudomembranous colitis. Am J Gastroenterol. 1982;77:220–221
  15. Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol. 1985;80:867–868
  16. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97:1769–1775
  17. Surawicz CM, McFarland LV, Elmer G, et al. Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am J Gastroenterol. 1989;84:1285–1287
  18. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271:1913–1918
  19. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000;31:1012–1017
  20. Leung DY, Kelly CP, Boguniewicz M, et al. Treatment with intravenously administered γ globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr. 1991;118:633–637
  21. Salcedo J, Keates S, Pothoulakis C, et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut. 1997;41:366–370
  22. Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother. 2004;53:882–884
  23. Sougioultzis S, Kyne L, Drudy D, et al. Clostridium difficile toxoid vaccine in recurrent C difficile-associated diarrhea. Gastroenterology. 2005;128:764–770
  24. McPherson S, Rees CJ, Ellis R, et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum. 2006;49:640–645
  25. Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357:189–193
  26. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40:1591–1597
  27. Nair S, Yadav D, Corpuz M, et al. Clostridium difficile colitis: factors influencing treatment failure and relapse—a prospective evaluation. Am J Gastroenterol. 1998;93:1873–1876
  28. Aronsson B, Granstrom M, Mollby R, et al. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection. 1985;13:97–101
  29. Bacon AE, Fekety R. Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic-associated diarrhea. Diagn Microbiol Infect Dis. 1994;18:205–209
  30. Warny M, Vaerman JP, Avesani V, et al. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun. 1994;62:384–389
  31. Kyne L, Warny M, Qamar A, et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342:390–397
  32. Charlson ME, Sax FL, MacKenzie CR, et al. Assessing illness severity: does clinical judgment work?. J Chronic Dis. 1986;39:439–452
  33. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383
  34. Horn SD, Sharkey PD, Bertram DA. Measuring severity of illness: homogeneous case mix groups. Med Care. 1983;21:14–30
  35. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29–36
  36. Do AN, Fridkin SK, Yechouron A, et al. Risk factors for early recurrent Clostridium difficile-associated diarrhea. Clin Infect Dis. 1998;26:954–959
  37. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171:466–472
  38. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442–2449
  39. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433–2441
  40. Kyne L, Sougioultzis S, McFarland LV, et al. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol. 2002;23:653–659
  41. Johnson S, Schriever C, Galang M, et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007;44:846–848
  42. Louie TJ, Peppe J, Watt CK, et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis. 2006;43:411–420

 Conflicts of interest The authors disclose the following: During the past 2 years, Ciarán P. Kelly has acted as a scientific consultant for Acambis, Actelion, BioHelix, Genzyme, Replidyne, Salix, and ViroPharm and has received research grant funding from Actelion Inc, Genzyme Inc, Massachusetts Biologics Laboratories, Medarex Inc, and Salix Pharmaceuticals, companies that are producing or developing treatments for C difficile infection. No potential conflicts of interest exist for other authors.

 Funding Supported by grants from the National Institutes of Health (RO-1 AI053069 (to C.P.K.); K30-HL04095 for the Scholars in Clinical Science Program at Harvard Medical School (in which Mary Y. Hu was enrolled); and T32-DK0776 (to S.M. and D.A.L.); and the Irish Health Research Board (RP/2005/72, to L.K.).

PII: S0016-5085(08)02262-2

doi: 10.1053/j.gastro.2008.12.038

Gastroenterology
Volume 136, Issue 4 , Pages 1206-1214 , April 2009

Article Tools

* Image Usage & Resolution